The Journal of clinical endocrinology and metabolism
-
J. Clin. Endocrinol. Metab. · Feb 2015
Randomized Controlled Trial Multicenter StudyEffects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.
Abaloparatide is a novel synthetic peptide analog of parathyroid hormone-related protein (PTHrP) that is currently being developed as a potential anabolic agent in the treatment of postmenopausal osteoporosis. ⋯ Compared with placebo, 24 weeks of daily sc abaloparatide increases BMD of the lumbar spine, femoral neck, and total hip in a dose-dependent fashion. Moreover, the abaloparatide-induced BMD increases at the total hip are greater than with the marketed dose of teriparatide. These results support the further investigation of abaloparatide as an anabolic therapy in postmenopausal osteoporosis.
-
J. Clin. Endocrinol. Metab. · Feb 2015
Review Meta AnalysisClinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis.
Various drugs affect body weight as a side effect. ⋯ Several drugs are associated with weight change of varying magnitude. Data are provided to guide the choice of drug when several options exist and institute preemptive weight loss strategies when obesogenic drugs are prescribed.
-
J. Clin. Endocrinol. Metab. · Feb 2015
Observational StudyAssociation of vitamin D status of septic patients in intensive care units with altered procalcitonin levels and mortality.
The purpose of this study was to determine whether vitamin D levels correlate with procalcitonin (PCT) levels and mortality in septic patients. ⋯ Lower serum 25OHD levels at ICU admission were associated with 28-day mortality in septic patients. Serum 25OHD levels were inversely correlated with PCT levels. Hypovitaminosis D was associated with higher mortality rates in PTH responders than in nonresponders.